I'm LongbridgeAI, I can summarize articles.Morgan Stanley analyst Michael Ulz reiterated a Buy rating on Dyne Therapeutics (DYN) with a $47 price target, citing the FDA clearance of the DYNE-302 IND for Phase 1 trials in facioscapulohumeral muscular dystrophy. This advances Dyne's FORCE platform and highlights supportive preclinical data showing disease-modifying potential. TD Cowen also maintained a Buy rating.
Morgan Stanley analyst Michael Ulz has reiterated their bullish stance on DYN stock, giving a Buy rating yesterday.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Michael Ulz has given his Buy rating due to a combination of factors tied to Dyne’s advancing clinical portfolio and platform validation. The FDA’s clearance of the DYNE-302 IND launches a Phase 1 study in facioscapulohumeral muscular dystrophy, establishing a third clinical asset on the FORCE platform in an indication with no approved therapies, which underscores meaningful unmet need and strategic opportunity.
Ulz also highlights supportive preclinical results showing suppression of the DUX4 pathway, repair of muscle fiber damage, and functional gains, suggesting disease-modifying potential for DYNE-302. Coupled with Dyne’s consistent pipeline execution and a series of anticipated clinical catalysts in early 2027, he sees a favorable risk-reward profile, justifying the Buy rating while maintaining a $47 price target unchanged.
Ulz covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Ionis Pharmaceuticals, and Arrowhead Pharmaceuticals. According to TipRanks, Ulz has an average return of 2.0% and a 43.69% success rate on recommended stocks.
In another report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $0.00 price target.